Lilly, Incyte: Baricitinib Reduced Deaths In COVID-19 Patients Under Invasive Mechanical Ventilation

 Eli Lilly and Co. (LLY) and Incyte (INCY) Tuesday said that new data from Phase 3 COV-BARRIER sub-study indicated that baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation.

As per the data, one death prevented for every six baricitinib-treated patients on mechanical ventilation compared to placebo.

Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly.

Lilly said it intends to publish detailed results from this additional sub-study in a peer-reviewed journal and present the findings at a medical meeting in the coming months. These new data from the COV-BARRIER sub-study will also be shared with regulatory authorities in the U.S., European Union and other geographies.

https://www.nasdaq.com/articles/lilly-incyte%3A-baricitinib-reduced-deaths-in-covid-19-patients-under-invasive-mechanical